Up 13% in a month, Polynovo share price bounces back after being dumped from ASX 200

What's going on with the Polynovo share price?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Polynovo share price has surged nearly 13% in a month 
  • In the past year, the company's share price has rocketed 50% 
  • Managers have been buying up Polynovo shares, potentially a sign of management confidence 

The Polynovo Ltd (ASX: PNV) share price has jumped ahead in the past month despite losing its place on the ASX 200.

The company's share price has jumped nearly 13% from $1.185 at market close on 3 June to the current price of $1.335. In contrast, the S&P/ASX 200 Index (ASX: XJO) has lost nearly 9% in the same time frame.

So why has the Polynovo share price had such a good month?

Two happy scientists analysing test results in a lab

Image source: Getty Images

Why has the Polynovo share price risen?

Polynovo is an ASX healthcare share working on medical devices, using patented technology Novosorb.

Polynovo shares have jumped amid insider trading among the company's management.

The company's chair David Williams bought $284,142 worth of shares on 6 June and 7 June alone. In total, he purchased 250,000 shares in these two days.

Williams has purchased more than $5 million worth of shares since the start of May, as my Foolish colleague Aaron reported.

Insider buying can be a sign that management is optimistic about the future direction of a company.

Polynovo reported record revenue of $12.6 million in the March quarter, up 59% compared to the same time in the previous year. The company's ANZ sales picked up substantially in the quarter, up 81.9% compared to the same time last year.

In recent news, Polynovo has completed settlement on the sale of its headquarters in Port Melbourne.

The company's headquarters sold for $6.35 million.

In recent times, Polynovo shares have made the list of the 10 most shorted ASX shares. However, as my Foolish colleague James reported, short interest in the company has eased to 7.9%.

Polynovo share price snapshot

The Polynovo share price has descended 50% in the past 12 months, while it is down 12% in the year to date.

In comparison, the benchmark ASX 200 has lost nearly 10% over the past year.

Polynovo has a market capitalisation of nearly $884 million based on today's share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why ResMed shares are tumbling 6% today despite strong results

Here's what spooked investors.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Imricor Medical Systems shares: Philips declares compatibility for iMR products

Big news is catching the eye of investors on Friday.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Earnings Results

ResMed posts strong Q4 earnings, lifts dividend

The sleep disorder treatment company had another record quarter.

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals reports clinical trial milestones

Clarity Pharmaceuticals reported continued clinical progress for its prostate cancer imaging and therapy programs.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?

This healthcare stock keeps rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose

Clarity Pharmaceuticals reports further progress in its SECuRE prostate cancer trial, showing strong PSA responses and new complete responses at…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade

Second quarter net sales of DAYBUE increased 30%.

Read more »